跳至主要内容
临床试验/NCT02020499
NCT02020499终止不适用

Non-interventional, Observational, Long Term Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Patients With Acromegaly.

Ipsen5 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2014年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
发起方
Ipsen
入组人数
5
试验地点
5
主要终点
Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline

研究概览

简要总结

This is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for Somatuline Autogel treatment in patients with Acromegaly.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Acromegaly.
  • Males and females aged 18 years and older.
  • Signed informed consent (patient must give consent to the collection of retrospective data).
  • Patients who have had surgery may enter the study 3 months post-surgery and evaluated for the duration of the study.
  • With the intention to be treated with ATG (decision to prescribe ATG made prior to inclusion into the study) or already being treated with ATG.
  • If already being treated with ATG:
  • Previous ATG treatment maximum of 3 months. AND Minimum data available (demographic data, disease history including previous treatments, GH, IGF-1 levels at baseline and under treatment as applicable).
  • Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other somatostatin analogues) for the treatment or symptom control of acromegaly.

排除标准

  • The subject has had radiotherapy in the last 5 years.
  • The subject has had surgery in the last 3 months.
  • The subject has already been included in this study.
  • Participation in an interventional trial, or receiving experimental drug.

研究组 & 干预措施

Acromegalic patients

Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)

干预措施: Somatuline Autogel® (lanreotide) 60, 90, 120 mg. (Drug)

结局指标

主要结局

Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline

时间窗: Baseline and 4 weeks

次要结局

  • Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline(Baseline, 1 year and 3 years)

研究者

发起方
Ipsen
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验